Investing Ideas
/
Swiss Pharmaceuticals & Biotech Undervalued based on future growth

Swiss Pharmaceuticals & Biotech Undervalued based on future growth

Name: Financial Insights Based on S&P Global Market Intelligence
Creator: Simply Wall St Pty Ltd
License: https://www.spglobal.com/content/dam/spglobal/corporate/en/documents/secure/MI-FastTrack-Terms-and-Conditions-July-2023.pdf

Results

0 new

Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)

1 companies

	Company	Last Price	7D Return	1Y Return	Market Cap	Analysts Target	Valuation	Growth	Div Yield
	SANN Santhera Pharmaceuticals Holding	CHF 12.70	21.4%	29.5%	CHF 153.7m	CHF 32.00	PE2.4x	E35.4%	n/a

Page 1 of 1